IL162540A0 - Bispecific antisense olignucleotides that inhibit igfbp-2 and igfbp-5 and methods of using same - Google Patents

Bispecific antisense olignucleotides that inhibit igfbp-2 and igfbp-5 and methods of using same

Info

Publication number
IL162540A0
IL162540A0 IL16254003A IL16254003A IL162540A0 IL 162540 A0 IL162540 A0 IL 162540A0 IL 16254003 A IL16254003 A IL 16254003A IL 16254003 A IL16254003 A IL 16254003A IL 162540 A0 IL162540 A0 IL 162540A0
Authority
IL
Israel
Prior art keywords
igfbp
methods
same
inhibit
bispecific antisense
Prior art date
Application number
IL16254003A
Other languages
English (en)
Original Assignee
Univ British Columbia
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ British Columbia filed Critical Univ British Columbia
Publication of IL162540A0 publication Critical patent/IL162540A0/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/713—Double-stranded nucleic acids or oligonucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C12N2310/111—Antisense spanning the whole gene, or a large part of it
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/35—Nature of the modification
    • C12N2310/351—Conjugate
    • C12N2310/3519—Fusion with another nucleic acid
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/50—Physical structure
    • C12N2310/51—Physical structure in polymeric form, e.g. multimers, concatemers

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
IL16254003A 2002-01-17 2003-01-17 Bispecific antisense olignucleotides that inhibit igfbp-2 and igfbp-5 and methods of using same IL162540A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US35004602P 2002-01-17 2002-01-17
PCT/CA2003/000061 WO2003062421A1 (en) 2002-01-17 2003-01-17 Bispecific antisense olignucleotides that inhibit igfbp-2 and igfbp-5 and methods of using same

Publications (1)

Publication Number Publication Date
IL162540A0 true IL162540A0 (en) 2005-11-20

Family

ID=27613360

Family Applications (2)

Application Number Title Priority Date Filing Date
IL16254003A IL162540A0 (en) 2002-01-17 2003-01-17 Bispecific antisense olignucleotides that inhibit igfbp-2 and igfbp-5 and methods of using same
IL16254004A IL162540A (en) 2002-01-17 2004-06-15 Bispecific antisense oligonucleotides that inhibit igfbp-2 and igfbp-5 and pharmaceutical compositions comprising the same

Family Applications After (1)

Application Number Title Priority Date Filing Date
IL16254004A IL162540A (en) 2002-01-17 2004-06-15 Bispecific antisense oligonucleotides that inhibit igfbp-2 and igfbp-5 and pharmaceutical compositions comprising the same

Country Status (15)

Country Link
US (11) US20030158143A1 (enExample)
EP (1) EP1465995B1 (enExample)
JP (1) JP4491240B2 (enExample)
KR (2) KR101265180B1 (enExample)
AT (1) ATE402999T1 (enExample)
AU (1) AU2003237616B2 (enExample)
CA (1) CA2469685C (enExample)
DE (1) DE60322509D1 (enExample)
DK (1) DK1465995T3 (enExample)
ES (1) ES2307942T3 (enExample)
HU (1) HU229452B1 (enExample)
IL (2) IL162540A0 (enExample)
NO (1) NO333017B1 (enExample)
NZ (1) NZ533126A (enExample)
WO (1) WO2003062421A1 (enExample)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6900187B2 (en) 1999-02-26 2005-05-31 The University Of British Columbia TRPM-2 antisense therapy using an oligonucleotide having 2′-O-(2-methoxy)ethyl modifications
IL144975A0 (en) 1999-02-26 2002-06-30 Univ British Columbia A composition containing an antisense oligonucleotide
US7569551B2 (en) 2000-02-25 2009-08-04 The University Of British Columbia Chemo- and radiation-sensitization of cancer by antisense TRPM-2 oligodeoxynucleotides
KR101265180B1 (ko) * 2002-01-17 2013-05-29 더 유니버시티 오브 브리티쉬 콜롬비아 아이지에프비피-2 및 아이지에프비피-5를 억제하는 양특이성 안티센스 올리고뉴클레오티드, 이를 이용하여 약학적 조성물을 제조하는 방법 및 그 약학적 조성물
EP1530636B1 (en) 2002-08-21 2010-08-18 The University Of British Columbia Treatment of melanoma by reduction in clusterin levels
KR101117673B1 (ko) 2002-08-21 2012-03-07 더 유니버시티 오브 브리티쉬 콜롬비아 암-관련 단백질을 표적으로 하는 알엔에이아이 프로브
AU2003297259A1 (en) * 2002-11-14 2004-06-03 Wyeth Methods and compositions for treating neurological disorders
CA2539727C (en) 2003-10-01 2016-11-01 The University Of British Columbia Bispecific oligonucleotide for the treatment of cns malignancies
US8710020B2 (en) 2004-04-02 2014-04-29 The University Of British Columbia Clusterin antisense therapy for treatment of cancer
US7482158B2 (en) * 2004-07-01 2009-01-27 Mathison Brian H Composite polynucleic acid therapeutics
DK1814595T3 (da) * 2004-11-23 2014-03-31 Univ British Columbia Behandling af cancer med en kombination af et middel, som forstyrrer EGF-signalvejen og et oligonucleotid, som reducerer clusterinniveauerne
US7315916B2 (en) * 2004-12-16 2008-01-01 Sandisk Corporation Scratch pad block
JP5376948B2 (ja) 2005-09-13 2013-12-25 ナショナル リサーチ カウンシル オブ カナダ 腫瘍細胞活性を調節する方法及び組成物
US8329399B2 (en) * 2006-10-27 2012-12-11 Siu K W Michael Endometrial biomarkers
WO2011063523A1 (en) 2009-11-24 2011-06-03 Alethia Biotherapeutics Inc. Anti-clusterin antibodies and antigen binding fragments and their use to reduce tumor volume
WO2011109262A2 (en) 2010-03-01 2011-09-09 Tau Therapeutics Llc Cancer diagnosis and imaging
WO2012156817A2 (en) * 2011-05-19 2012-11-22 Teva Pharmaceutical Industries Ltd. Method for treating non-small cell lung cancer
SG10201601917XA (en) 2011-09-12 2016-04-28 Tau Therapeutics Llc Antagonists of products of the hs.459642 unigene cluster for the inhibition of proliferation, development or differentiation of stem cells including cancer stem cells
CA2862739A1 (en) 2012-02-22 2013-08-29 Alethia Biotherapeutics Inc. Co-use of a clusterin inhibitor with an egfr inhibitor to treat cancer
CA2844640A1 (en) * 2013-12-06 2015-06-06 The University Of British Columbia Method for treatment of castration-resistant prostate cancer
KR102755601B1 (ko) * 2015-10-14 2025-01-17 바이오-패쓰 홀딩스 인크. 리포좀 제제를 위한 p-에톡시 핵산
FI3364993T3 (fi) 2015-10-22 2023-01-13 Menetelmiä angelmanin oireyhtymän hoitamiseksi
US10496215B2 (en) * 2016-04-29 2019-12-03 Synaptics Incorporated Sensing for touch and force
US10927379B2 (en) 2016-09-16 2021-02-23 Bio-Path Holdings, Inc. Combination therapy with liposomal antisense oligonucleotides
CA3053781A1 (en) 2017-02-15 2018-08-23 Cavion, Inc. Benzopyran and naphalene derivatives and their uses as calium channel inhibitors
IL269608B2 (en) 2017-04-19 2024-06-01 Bio Path Holdings Inc Compositions comprising p-ethoxy nucleic acids for stat3 inhibition for use in treating cancer or autoimmune disease
US12234457B2 (en) 2017-04-19 2025-02-25 Bio-Path Holdings, Inc. P-ethoxy nucleic acids for BCL2 inhibition
CA3061720A1 (en) 2017-04-26 2018-11-01 Cavion, Inc. Methods for improving memory and cognition and for treating memory and cognitive disorders
KR102068302B1 (ko) 2018-07-25 2020-01-20 정준모 봉투 고정장치
JP7480131B2 (ja) 2018-10-03 2024-05-09 カビオン・インコーポレイテッド （ｒ）－２－（４－イソプロピルフェニル）－ｎ－（１－（５－（２，２，２－トリフルオロエトキシ）ピリジン－２－イル）エチル）アセトアミドを使用した本態性振戦の処置

Family Cites Families (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH06503949A (ja) 1990-08-28 1994-05-12 カイロン　コーポレイション 新規インシュリン様成長因子結合タンパク質ｉｇｆｂｐ―５
CA2090705A1 (en) 1990-08-28 1992-03-01 Michael C. Kiefer Genetic material encoding igfbp-5
US5721237A (en) * 1991-05-10 1998-02-24 Rhone-Poulenc Rorer Pharmaceuticals Inc. Protein tyrosine kinase aryl and heteroaryl quinazoline compounds having selective inhibition of HER-2 autophosphorylation properties
US5646042A (en) * 1992-08-26 1997-07-08 Ribozyme Pharmaceuticals, Inc. C-myb targeted ribozymes
US5417978A (en) * 1993-07-29 1995-05-23 Board Of Regents, The University Of Texas System Liposomal antisense methyl phosphonate oligonucleotides and methods for their preparation and use
US5801154A (en) * 1993-10-18 1998-09-01 Isis Pharmaceuticals, Inc. Antisense oligonucleotide modulation of multidrug resistance-associated protein
WO1995017507A1 (en) * 1993-12-23 1995-06-29 Biognostik Gesellschaft für Biomolekulare Diagnostik mbH ANTISENSE NUCLEIC ACIDS FOR THE PREVENTION AND TREATMENT OF DISORDERS IN WHICH EXPRESSION OF c-erbB PLAYS A ROLE
AUPM672594A0 (en) * 1994-07-08 1994-08-04 Royal Children's Hospital Research Foundation A method for the prophylaxis and/or treatment of proliferative and/or inflammatory skin disorders
US5789389A (en) * 1995-03-17 1998-08-04 Board Of Trustees Of University Of Illinois BCL2 derived genetic elements associated with sensitivity to chemotherapeutic drugs
US5855911A (en) * 1995-08-29 1999-01-05 Board Of Regents, The University Of Texas System Liposomal phosphodiester, phosphorothioate, and P-ethoxy oligonucleotides
ES2221039T3 (es) * 1996-02-14 2004-12-16 Isis Pharmaceuticals, Inc. Oligonucleotidos abiertos modificados con azucar.
US5910583A (en) * 1996-11-04 1999-06-08 Duke University Antisense oligonucleotides against ERBB-2
US6383808B1 (en) 2000-09-11 2002-05-07 Isis Pharmaceuticals, Inc. Antisense inhibition of clusterin expression
US6133246A (en) * 1997-08-13 2000-10-17 Isis Pharmaceuticals Inc. Antisense oligonucleotide compositions and methods for the modulation of JNK proteins
US6335194B1 (en) * 1998-09-29 2002-01-01 Isis Pharmaceuticals, Inc. Antisense modulation of survivin expression
US6210892B1 (en) * 1998-10-07 2001-04-03 Isis Pharmaceuticals, Inc. Alteration of cellular behavior by antisense modulation of mRNA processing
US6172216B1 (en) * 1998-10-07 2001-01-09 Isis Pharmaceuticals Inc. Antisense modulation of BCL-X expression
WO2000031048A1 (en) 1998-11-19 2000-06-02 Warner-Lambert Company N-[4-(3-chloro-4-fluoro-phenylamino)-7-(3-morpholin-4-yl-propoxy)-quinazolin-6-yl]-acrylamide, an irreversible inhibitor of tyrosine kinases
WO2000034469A1 (en) 1998-12-11 2000-06-15 The Research Foundation Of State University Of New York At Albany Compositions and methods for altering cell migration
IL144975A0 (en) 1999-02-26 2002-06-30 Univ British Columbia A composition containing an antisense oligonucleotide
US6900187B2 (en) 1999-02-26 2005-05-31 The University Of British Columbia TRPM-2 antisense therapy using an oligonucleotide having 2′-O-(2-methoxy)ethyl modifications
US5998148A (en) * 1999-04-08 1999-12-07 Isis Pharmaceuticals Inc. Antisense modulation of microtubule-associated protein 4 expression
WO2000069454A1 (en) * 1999-05-17 2000-11-23 Board Of Regents, The University Of Texas System Suppression of endogenous igfbp-2 to inhibit cancer
AU768904B2 (en) * 1999-06-21 2004-01-08 Murdoch Childrens Research Institute, The A method for the prophylaxis and/or treatment of medical disorders
CA2373721C (en) 1999-07-02 2013-10-15 Genentech, Inc. Compounds that bind her2
EP1200579B1 (en) * 1999-07-19 2008-04-23 The University of British Columbia Antisense therapy for hormone-regulated tumors
US6310047B1 (en) * 1999-08-24 2001-10-30 Virginia Commonwealth University High affinity DNA binding compounds as adjuvants in antisense technology
WO2001046455A2 (en) 1999-12-21 2001-06-28 Yale University Survivin promotion of angiogenesis
US7569551B2 (en) * 2000-02-25 2009-08-04 The University Of British Columbia Chemo- and radiation-sensitization of cancer by antisense TRPM-2 oligodeoxynucleotides
EP1309726B2 (en) 2000-03-30 2018-10-03 Whitehead Institute For Biomedical Research Rna sequence-specific mediators of rna interference
US7196067B2 (en) * 2000-09-14 2007-03-27 The University Of British Columbia Antisense insulin-like growth factor binding protein (IGFBP)-2-oligodeoxynucleotides for prostate and other endocrine tumor therapy
RU2322500C2 (ru) * 2000-12-01 2008-04-20 Макс-Планк-Гезелльшафт Цур Фердерунг Дер Виссеншафтен Е.Ф. Малые молекулы рнк, опосредующие интерференцию рнк
EP1390472A4 (en) * 2001-05-29 2004-11-17 Sirna Therapeutics Inc NUCLEIC ACID TREATMENT OF DISEASES OR SIDES RELATED TO RAS, HER2 AND HIV LEVELS
US6750019B2 (en) * 2001-10-09 2004-06-15 Isis Pharmaceuticals, Inc. Antisense modulation of insulin-like growth factor binding protein 5 expression
DE10152005A1 (de) 2001-10-22 2003-04-30 Bayer Cropscience Ag Pyrazolylsubstituierte Heterocyclen
US20050123896A1 (en) 2001-10-25 2005-06-09 Benz Christopher C. Screening system for modulators of her2 mediated transcription and her2 modulators identified thereby
KR101265180B1 (ko) * 2002-01-17 2013-05-29 더 유니버시티 오브 브리티쉬 콜롬비아 아이지에프비피-2 및 아이지에프비피-5를 억제하는 양특이성 안티센스 올리고뉴클레오티드, 이를 이용하여 약학적 조성물을 제조하는 방법 및 그 약학적 조성물
CA2485589A1 (en) * 2002-05-14 2003-11-27 Baylor College Of Medicine Small molecule inhibitors of her2 expression
EP1530636B1 (en) 2002-08-21 2010-08-18 The University Of British Columbia Treatment of melanoma by reduction in clusterin levels
KR101117673B1 (ko) * 2002-08-21 2012-03-07 더 유니버시티 오브 브리티쉬 콜롬비아 암-관련 단백질을 표적으로 하는 알엔에이아이 프로브
WO2004092378A2 (en) * 2003-04-18 2004-10-28 The University Of British Columbia Method for treatment of cancerous angiogenic disorders
CA2539727C (en) * 2003-10-01 2016-11-01 The University Of British Columbia Bispecific oligonucleotide for the treatment of cns malignancies
PE20121495A1 (es) * 2009-07-30 2012-11-19 Antisense Pharma Gmbh Combinacion de un agente quimioterapeutico y un inhibidor del sistema tgf-beta

Also Published As

Publication number Publication date
US7928082B2 (en) 2011-04-19
US8541390B2 (en) 2013-09-24
US8252765B2 (en) 2012-08-28
US20110196019A1 (en) 2011-08-11
NZ533126A (en) 2006-04-28
DE60322509D1 (de) 2008-09-11
HU229452B1 (en) 2013-12-30
IL162540A (en) 2011-06-30
US20130096180A1 (en) 2013-04-18
NO333017B1 (no) 2013-02-18
CA2469685C (en) 2013-03-12
NO20043401L (no) 2004-10-13
ATE402999T1 (de) 2008-08-15
HUP0402543A3 (en) 2012-09-28
US20030158143A1 (en) 2003-08-21
US9101646B2 (en) 2015-08-11
AU2003237616B2 (en) 2007-07-05
US20120220646A1 (en) 2012-08-30
US8835401B2 (en) 2014-09-16
DK1465995T3 (da) 2008-10-20
US8470796B2 (en) 2013-06-25
CA2469685A1 (en) 2003-07-31
US8580761B2 (en) 2013-11-12
US20160002630A1 (en) 2016-01-07
WO2003062421A1 (en) 2003-07-31
EP1465995B1 (en) 2008-07-30
KR101265180B1 (ko) 2013-05-29
ES2307942T3 (es) 2008-12-01
US20060122141A1 (en) 2006-06-08
US20080261912A1 (en) 2008-10-23
US7973017B2 (en) 2011-07-05
US20100267808A1 (en) 2010-10-21
EP1465995A1 (en) 2004-10-13
JP4491240B2 (ja) 2010-06-30
KR101166214B1 (ko) 2012-07-16
JP2005514948A (ja) 2005-05-26
KR20040085150A (ko) 2004-10-07
US20110190382A1 (en) 2011-08-04
US20120077861A1 (en) 2012-03-29
KR20110026023A (ko) 2011-03-14
US8389491B2 (en) 2013-03-05
HUP0402543A2 (hu) 2005-03-29
US20130303592A1 (en) 2013-11-14

Similar Documents

Publication Publication Date Title
HU229452B1 (en) Bispecific antisense olignucleotides that inhibit igfbp-2 and igfbp-5 and methods of using same
IL197159A (en) Two-stranded rna molecules that complement a sense or antisense strand of a human encoding igfbp-2 and igfbp-5, preparations containing them and their uses
DE60024660D1 (de) Menschliche rnase h und entsprechende oligonukleotidverbindungen
IL166780A0 (en) Use of ikappab-kinase inhibitors in pain therapy
IL174175A0 (en) Methods of treating autoimmune diseases using il-21
MXPA05012421A (es) Tratamiento sinergistico de cancer usando inmunomeros junto con agentes quimioterapeuticos.
IL164808A0 (en) Treatment of hypertesion in women receiving hormone replacement therapy
EP1613266A4 (en) METHOD FOR TREATING PAIN AND COMPOSITIONS FOR USE THEREOF
AU2003243059A8 (en) Use of repression blocking sequences in methods for enhancing gene expression
AU2002332472A8 (en) Compositions and methods for treating female sexual arousal disorder using hydrophobic-calcitonin gene related peptide
WO2004016215A3 (en) Use of antisense oligonucleotides to inhibit the expression of akt-1
IL149416A0 (en) Human enzymes of the metalloprotease family
AU2003206945A8 (en) Use of proteinase inhibitors in the treatment of autoimmune diseases
TW200504210A (en) A nucleolin antisense inhibiting growth of cancer cell
AU2003213105A8 (en) Methods and compositions in treating pain using diacylglycerol kinase epsilon
PL376755A1 (pl) Zastosowanie R-10-hydroksy-10,11-dihydrokarbamazepiny w bólach neuropatycznych
MXPA05008817A (es) Derivados de esteres lipidos de nucleotidos.
PT1163333E (pt) ''inibidores da síntese de endotelina-1''
UA87117C2 (ru) Применение пептидных соединений для лечения центральной невропатической боли
AU2003299872A8 (en) Vmp-like sequences of pathogenic borrelia species and strains
GB2385853B (en) Method of generation and management of unique sequences in DNA production
AU2003293582A8 (en) Stimulation of hair regrowth
TW200628168A (en) Use of organic compounds
GB0423126D0 (en) Protein
AU2003273247A8 (en) Non-invasive methods to identify agents for treating pain